 AbbVie Inc NYSE: ABBV has terminated its license and collaboration agreement with Molecular Partners AG NASDAQ: MOLN for abicipar pegol for neovascular age-related macular degeneration nAMD and Diabetic Macular Edema DME. As such, Molecular Partners will regain the development and commercial rights of abicipar on a worldwide basis. 